<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604328</url>
  </required_header>
  <id_info>
    <org_study_id>LATA-CS101</org_study_id>
    <nct_id>NCT03604328</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma</brief_title>
  <official_title>An Open-label Phase I Study to Evaluate the Safety, Tolerability and Biodegradation Period of PolyActiva PA5108 Ocular Implant When Administered Intracamerally to the Anterior Chamber of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyActiva Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PolyActiva Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre, open label, study to assess the safety, tolerability and biodegradation of
      PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who are currently managing their Open Angle Glaucoma with combination drop
      therapy will be recruited. Drop therapy will cease in the treatment eye and continue in the
      contralateral eye. The treated eye will receive via injection, a single PA5108 ocular
      implant. Participants will be monitored for safety and tolerability of the ocular implant
      until it completely biodegrades.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by the occurrence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timeframe to complete implant biodegradation based on implant size and location</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>PA5108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA5108</intervention_name>
    <description>single ocular implant, administered on day 1</description>
    <arm_group_label>PA5108</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade 3 or 4 open angle glaucoma (Shaffer-Etienne scale)

          -  Visual acuity in non-study eye same or better than study eye

          -  Currently taking topical ocular hypotensive medication including a prostaglandin
             analogue

        Exclusion Criteria:

          -  Aphakic eyes

          -  Only one eye

          -  History of, or current uveitis, Cystoid Macular Edema (CME) or cornea edema

          -  Intraocular surgery or cornea/refractive surgery in study eye in past 6 months or
             anticipate need for eye surgery (including laser) in study eye during study period

          -  Current retinal detachment

          -  Uncontrolled infection in the eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Kerr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Victorian Eye &amp; Ear Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

